FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Pharm Exec10h
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
The American Journal of Managed Care3d
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
MedPage Today3d
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Scientists Are Developing Brain Implants That Could Revolutionize Parkinson’s Treatment
Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.
FiercePharma3d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
New Atlas2d
US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
Laxxon Medical Announces Positive Pilot PK Study Results for Advanced Levodopa/Carbidopa Asset for Parkinson's Disease, LMX.5
The LXM.5 pilot study reveals an 80% bioavailability increase compared to competing products combining levodopa and carbidopa. The study additionally shows sustained and smooth levodopa levels in the ...